BR9913630A - Vacina contra doenças sexualmente transmitidas - Google Patents

Vacina contra doenças sexualmente transmitidas

Info

Publication number
BR9913630A
BR9913630A BR9913630A BR9913630A BR9913630A BR 9913630 A BR9913630 A BR 9913630A BR 9913630 A BR9913630 A BR 9913630A BR 9913630 A BR9913630 A BR 9913630A BR 9913630 A BR9913630 A BR 9913630A
Authority
BR
Brazil
Prior art keywords
sexually transmitted
transmitted diseases
vaccine
vaccine against
against sexually
Prior art date
Application number
BR9913630A
Other languages
English (en)
Portuguese (pt)
Inventor
Moncef Mohamed Slaoui
Pierre G Vandepapeliere
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9913630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of BR9913630A publication Critical patent/BR9913630A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9913630A 1998-09-11 1999-09-08 Vacina contra doenças sexualmente transmitidas BR9913630A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9819898A GB9819898D0 (en) 1998-09-11 1998-09-11 New vaccine and method of use
PCT/EP1999/006623 WO2000015255A1 (en) 1998-09-11 1999-09-08 Vaccine against sexually transmitted diseases

Publications (1)

Publication Number Publication Date
BR9913630A true BR9913630A (pt) 2001-05-22

Family

ID=10838766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913630A BR9913630A (pt) 1998-09-11 1999-09-08 Vacina contra doenças sexualmente transmitidas

Country Status (28)

Country Link
EP (1) EP1109574B1 (https=)
JP (1) JP2002524532A (https=)
KR (1) KR100777896B1 (https=)
CN (2) CN1325311A (https=)
AR (1) AR021798A1 (https=)
AT (1) ATE392214T1 (https=)
AU (1) AU744989B2 (https=)
BR (1) BR9913630A (https=)
CA (1) CA2343399C (https=)
CO (1) CO5090882A1 (https=)
CY (1) CY1108147T1 (https=)
CZ (1) CZ302808B6 (https=)
DE (1) DE69938555T2 (https=)
DK (1) DK1109574T3 (https=)
ES (1) ES2304068T3 (https=)
GB (1) GB9819898D0 (https=)
HU (1) HUP0104297A3 (https=)
IL (1) IL141843A0 (https=)
MY (1) MY122216A (https=)
NO (1) NO329522B1 (https=)
NZ (1) NZ510425A (https=)
PL (1) PL199545B1 (https=)
PT (1) PT1109574E (https=)
SI (1) SI1109574T1 (https=)
TR (1) TR200100948T2 (https=)
TW (1) TWI225790B (https=)
WO (1) WO2000015255A1 (https=)
ZA (1) ZA200101987B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
CA2699513C (en) 2007-09-12 2018-03-13 Novartis Ag Gas57 mutant antigens and gas57 antibodies
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
CA2843854A1 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
US11071745B2 (en) 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
JP7525976B2 (ja) * 2014-07-07 2024-07-31 エリアン リミテッド ライアビリティ カンパニー ウイルス予防治療方法及び曝露前予防キット
BR112018017141A2 (pt) 2016-02-22 2019-01-02 Boehringer Ingelheim Vetmedica Gmbh método para a imobilização de biomoléculas
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ATE157882T1 (de) * 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
HK1037978A1 (en) 2002-03-01
CZ2001887A3 (cs) 2001-10-17
EP1109574B1 (en) 2008-04-16
HUP0104297A3 (en) 2004-10-28
MY122216A (en) 2006-03-31
PL346651A1 (en) 2002-02-25
CA2343399A1 (en) 2000-03-23
TWI225790B (en) 2005-01-01
DK1109574T3 (da) 2008-06-30
DE69938555D1 (de) 2008-05-29
NZ510425A (en) 2003-04-29
PL199545B1 (pl) 2008-09-30
GB9819898D0 (en) 1998-11-04
IL141843A0 (en) 2002-03-10
CZ302808B6 (cs) 2011-11-23
ES2304068T3 (es) 2008-09-01
PT1109574E (pt) 2008-06-12
AU744989B2 (en) 2002-03-07
KR100777896B1 (ko) 2007-11-27
KR20010075049A (ko) 2001-08-09
NO329522B1 (no) 2010-11-01
EP1109574A1 (en) 2001-06-27
NO20011193L (no) 2001-05-09
AU5975299A (en) 2000-04-03
CA2343399C (en) 2010-08-03
ZA200101987B (en) 2002-05-09
DE69938555T2 (de) 2009-06-10
ATE392214T1 (de) 2008-05-15
TR200100948T2 (tr) 2001-07-23
SI1109574T1 (sl) 2008-08-31
JP2002524532A (ja) 2002-08-06
WO2000015255A1 (en) 2000-03-23
CY1108147T1 (el) 2014-02-12
AR021798A1 (es) 2002-08-07
CN1325311A (zh) 2001-12-05
CN101130070A (zh) 2008-02-27
HUP0104297A2 (hu) 2002-03-28
CO5090882A1 (es) 2001-10-30
NO20011193D0 (no) 2001-03-08

Similar Documents

Publication Publication Date Title
BR9913630A (pt) Vacina contra doenças sexualmente transmitidas
ZA200202475B (en) Antiviral compositions for tissue paper.
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
BR0314763A (pt) Tratamento de infecções fúngicas
EA200601132A1 (ru) Предупреждение и лечение амилоидогенного заболевания
BR9608648A (pt) Vacinas de vírus vivos prrs de baixa patogenicidade processos para sua preparação
BR9710585A (pt) Composição para administração enteral, processo para melhorar a resistência fìsica ou desempenho atlético de um mamìfero, para aumentar a concentração de proteìna, massa corporal sem gordura ou massa muscular em um mamìfero, para diminuir a deposição de gordura corporal para uma dada ingestão calórica e aumentar a perda de gordura corporal em um mamìfero, para tratar os efeitos catabólicos de doença em um mamìfero, para aperfeiçoar a resistência fìsica ou o desempenho atléticode um mamìfero, e, para aumentar a massa de um corpo de carne magra de um mamìfero e diminuir a deposição de gordura
PT782450E (pt) Utilizacao de inibidores da aromatase para a preparacao de um medicamento para o tratamento de uma carencia relativa de androgenio do homem
BR9712366A (pt) Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
MX9805441A (es) Compuestos terapeuticos.
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
Rudy Imiquimod (Aldara): modifying the immune response
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
PL348828A1 (en) New cancer treatments
NO981898D0 (no) Anvendelse av flupirtin for forhindring og behandling av sykdommer som er forbundet med skade pÕ det hematopotiske cellesystem
BR0311613A (pt) Métodos para inibição, tratamento ou prevenção de sintomas de atrofia da pele, ou atrofia epitelial ou da mucosa nas mulheres e utilização de composto
ES2173977T3 (es) Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.
BR0213162A (pt) Métodos para prevenção e tratamento da perda óssea com compostos esteróides
BR0208920A (pt) Inibidor de aromatase em dose única para tratamento de infertilidade
BR9709066A (pt) Estìmulo de mecanismos de defesa de hospedeiro contra desafios virais.
BR0208955A (pt) Inibidores de aromatase para tratamento de infertilidade

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.